Ownership and insider activity for Novo Nordisk A/S (NVO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease.
Price
| Price | $38.29 (closing price, October 28, 2026) |
| Market Cap | $168.9B |
| Exchange | NYSE |
| Country | DK |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 18.69B DKK | 18.85B DKK | 15.64B DKK | 15.47B DKK | 12.76B DKK | 10.72B DKK | 12.65B DKK | 14.39B DKK | 15.65B DKK | 26.46B DKK |
| Short-term Investments | 2.01B DKK | 0 | 0 | 0 | 0 | 6.76B DKK | 10.92B DKK | 15.84B DKK | 10.65B DKK | 498.0M DKK |
| Receivables | 24.20B DKK | 23.55B DKK | 26.89B DKK | 29.15B DKK | 32.18B DKK | 46.80B DKK | 57.51B DKK | 75.26B DKK | 87.41B DKK | 75.70B DKK |
| Inventory | 14.34B DKK | 15.37B DKK | 16.34B DKK | 17.64B DKK | 18.54B DKK | 19.62B DKK | 24.39B DKK | 31.81B DKK | 40.85B DKK | 49.62B DKK |
| Total Current Assets | 59.77B DKK | 60.08B DKK | 59.07B DKK | 62.46B DKK | 65.81B DKK | 85.59B DKK | 108.19B DKK | 139.65B DKK | 160.90B DKK | 172.45B DKK |
| Property, Plant & Equipment | 30.18B DKK | 35.25B DKK | 41.89B DKK | 50.55B DKK | 50.27B DKK | 55.36B DKK | 66.67B DKK | 90.96B DKK | 162.49B DKK | 208.38B DKK |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 4.35B DKK | 5.09B DKK | 4.46B DKK | 20.06B DKK | 19.84B DKK |
| Intangible Assets | 2.71B DKK | 3.33B DKK | 5.14B DKK | 5.83B DKK | 20.66B DKK | 38.83B DKK | 46.32B DKK | 55.94B DKK | 91.03B DKK | 110.21B DKK |
| Total Assets | 97.54B DKK | 102.36B DKK | 110.77B DKK | 125.61B DKK | 144.92B DKK | 194.51B DKK | 241.26B DKK | 314.49B DKK | 465.80B DKK | 542.90B DKK |
| Accounts Payable | 6.01B DKK | 5.61B DKK | 6.76B DKK | 6.36B DKK | 5.72B DKK | 8.87B DKK | 15.59B DKK | 25.61B DKK | 28.85B DKK | 19.76B DKK |
| Short-term Debt | 229.0M DKK | 1.69B DKK | 515.0M DKK | 659.0M DKK | 6.68B DKK | 12.86B DKK | 480.0M DKK | 5.30B DKK | 11.78B DKK | 12.02B DKK |
| Total Current Liabilities | 47.44B DKK | 47.06B DKK | 54.16B DKK | 58.98B DKK | 70.27B DKK | 99.52B DKK | 120.94B DKK | 169.66B DKK | 217.53B DKK | 215.66B DKK |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 9.65B DKK | 20.77B DKK | 15.98B DKK | 84.25B DKK | 110.37B DKK |
| Total Liabilities | 52.27B DKK | 52.54B DKK | 58.93B DKK | 68.02B DKK | 81.60B DKK | 123.76B DKK | 157.77B DKK | 207.93B DKK | 322.31B DKK | 348.86B DKK |
| Retained Earnings | 46.11B DKK | 48.98B DKK | 53.41B DKK | 57.82B DKK | 63.77B DKK | 72.00B DKK | 80.59B DKK | 104.84B DKK | 144.45B DKK | 195.30B DKK |
| Total Equity | 45.27B DKK | 49.81B DKK | 51.84B DKK | 57.59B DKK | 63.33B DKK | 70.75B DKK | 83.49B DKK | 106.56B DKK | 143.49B DKK | 194.05B DKK |
| Total Debt | 229.0M DKK | 1.69B DKK | 515.0M DKK | 4.48B DKK | 10.36B DKK | 26.64B DKK | 25.78B DKK | 27.01B DKK | 102.79B DKK | 130.96B DKK |
| Net Debt | -20.47B DKK | -17.16B DKK | -15.12B DKK | -10.99B DKK | -2.40B DKK | 9.16B DKK | 2.21B DKK | -3.22B DKK | 76.48B DKK | 104.00B DKK |
| Working Capital | 12.33B DKK | 13.02B DKK | 4.90B DKK | 3.47B DKK | -4.46B DKK | -13.92B DKK | -12.75B DKK | -30.01B DKK | -56.63B DKK | -43.21B DKK |
Financial Health
| Debt / Equity | 0.63 |
| Current Ratio | 0.87 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 4.23 |
Profitability
| Return on Equity | 59.09% |
| Return on Invested Capital | 29.73% |
| Return on Assets | 19.57% |
| Gross Margin | 80.65% |
| Operating Margin | 43.13% |
| Net Margin | 35.35% |
Related companies: MRK · AMGN · SNY · LLY · JNJ · ABBV · AZN · PFE
Explore sector: Healthcare · Drug Manufacturers - General
More sections of NVO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks